SQZ Biotechnologies Company (SQZB)
Market Cap | 825.75K |
Revenue (ttm) | 18.61M |
Net Income (ttm) | -76.11M |
Shares Out | 29.49M |
EPS (ttm) | -2.61 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 65,638 |
Open | 0.0466 |
Previous Close | 0.0465 |
Day's Range | 0.0466 - 0.0484 |
52-Week Range | 0.0101 - 0.2900 |
Beta | 1.67 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About SQZB
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC... [Read more]
Financial Performance
In 2022, SQZB's revenue was $21.48 million, a decrease of -20.74% compared to the previous year's $27.10 million. Losses were -$79.46 million, 15.6% more than in 2021.
Financial StatementsNews
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotec...
Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced the results for the proposals considered and voted upon by its shareholders at its s...
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial resul...
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatme...
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported second quarter 2023 financial results and recent p...
SQZ Biotechnologies Provides Update on Collaboration with Roche
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive s...
NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of S...
SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (the “Company” or “SQZ”), focused on unlocking the full potential of cell therapies, today announced that its Board of Direct...
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent po...
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirm...
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfo...
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ
NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such investors are advised to ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SQZ Biotechnologies Company - SQZ
New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such invest...
Bronstein, Gewirtz & Grossman, LLC Announces SQZ Biotechnologies Company (SQZ) Investigation
NEW YORK , Dec. 7, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against SQZ Biotechnologies Company ("SQZ" or "the Company") (NYSE:...
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company's Enhan...
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ) today announced the strategic prioritization of its clinical portfolio to concentrate on the development of its second-generation e...
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of...
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical data s...
SQZ Biotechnologies to Present at Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei,...
SQZ Biotechnologies Announces Leadership Transition
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernst...
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2022 financi...
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of...